Učitavanje...
The CYP3A biomarker 4β‐hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation
AIMS: Tacrolimus is a cornerstone in modern immunosuppressive therapy after kidney transplantation. Tacrolimus dosing is challenged by considerable pharmacokinetic variability, both between patients and over time after transplantation, partly due to variability in cytochrome P450 3A (CYP3A) activity...
Spremljeno u:
| Izdano u: | Br J Clin Pharmacol |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5465334/ https://ncbi.nlm.nih.gov/pubmed/28146606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13248 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|